Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Psilocybin/Psilocin
Clinical Pharmacology in Drug Development April 6, 2020 Elyes Dahmane, Paul R. Hutson, Jogarao Gobburu 44 citations
Abstract Psilocybin is being developed for treating major depressive disorder. Psilocybin is readily dephosphorylated to psilocin upon absorption. The potential for psilocin proarrhythmic effect was assessed using a concentration‐QTc interval (C‐QTc) analysis from an open‐label single ascending dose study of psilocybin. Psilocybin doses ranged from 0.3 to 0.6 mg/kg. This trial showed a...